The first warning sign was the delay in publishing assay results. The next was the Lithium brine acquisition despite the enthusiastic announcements and much celebrated 40km Pegmatite dyke at Morabisi.
So far, the only real and compelling asset is the technology to produce a price competitive biostimulant.
Of course this is only my view.
